Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05437393
Other study ID # 141267
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 2, 2023
Est. completion date July 31, 2024

Study information

Verified date June 2023
Source University College, London
Contact Rory J Piper, MRCS
Phone 20 7405 9200
Email rory.piper.20@ucl.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The CADET Pilot will investigate the safety and feasibility of deep brain stimulation (DBS) to treat children with Lennox-Gastaut syndrome using a novel DBS device (Picostim DyNeuMo-1). Following a 30-day preoperative/baseline assessment phase, all children will have a neurosurgical procedure to implant the device. Implantation will be followed by a 30-day phase of no stimulation (the device is off / inactive) and then a six-month phase of active stimulation (the device is on / active).


Description:

The CADET pilot will be a single-arm, multi-site, interventional clinical trial. This design has been chosen since this is a feasibility and safety trial in a small number of patients and thus does not primarily aim to determine efficacy. In this pilot clinical trial, four children with drug-resistant LGS will undergo bilateral CMN DBS. Following the DBS insertion, all children will undergo one month of inactive ('off') DBS in order to allow the lesioning effect of electrode implantation to dissipate. Thereafter, children will receive active ('on') DBS therapy with standard stimulation parameters for six-months. Following the 'on' phase of the trial, the child will then transition into continuing clinical care and will have their stimulation parameters altered according to clinical evaluation.


Recruitment information / eligibility

Status Recruiting
Enrollment 4
Est. completion date July 31, 2024
Est. primary completion date July 31, 2024
Accepts healthy volunteers No
Gender All
Age group 5 Years to 14 Years
Eligibility INCLUSION CRITERIA: Children enrolled in this study must: 1. Be 5-14 years of age at consent. 2. Have a diagnosis of Lennox-Gastaut Syndrome, as determined by: - Slow (<3.0Hz) spike-and-wave pattern and/or fast wave pattern (tonic seizures) on EEG for at least six-months months prior to the enrolment into the baseline period - History of drop seizures (tonic, atonic, or tonic-clonic) for at least six-months prior to the enrolment into the baseline period 3. Experience at least 10 seizures per month. 4. Have tried and not responded to two or more antiseizure medications prior to enrolment. 5. Be taking one or more anti-seizure medication(s) at a stable dose for at least the four weeks prior and have a parent/guardian(s) who is willing for their child's maintenance anti-seizure drugs to be unaltered for the trial duration. 6. If on a ketogenic diet, have been established on a stable ketogenic diet for at least 12 weeks prior to screening and the parent/guardian(s) to be willing for child to stay on a stable ketogenic for the duration of the trial. 7. Have a parent/guardian(s) who is willing and able to comply with all the requirements of the study, including the completion of the seizure diary and periodic device charging. ------------------------------- EXCLUSION CRITERIA: Children enrolled in this study must not: 1. Have had prior deep brain stimulation insertion. 2. Have an active ('on') vagus nerve stimulator (or active within the six months prior to the baseline period). 3. Have abnormal thalamic anatomy detected on imaging that would render DBS either unsafe or unfeasible. 4. Have a bleeding disorder. 5. Have medical conditions/factors that would increase their anaesthetic risk to an unacceptable level. 6. Have a nickel allergy 7. Be pregnant 8. Participate in contact sports

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Deep brain stimulation
Deep brain stimulation of the centromedian nucleus (bilateral)

Locations

Country Name City State
United Kingdom Great Ormond Street Hospital NHS Foundation Trust London
United Kingdom King's College Hospital NHS Foundation Trust London

Sponsors (5)

Lead Sponsor Collaborator
University College, London Great Ormond Street Hospital for Children NHS Foundation Trust, King's College Hospital NHS Trust, King's College London, University of Oxford

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Radiological correlates of neurophysiological and clinical response to CMN DBS Analysis of pre-trial MRI brain scan in conjunction with relative change in seizure counts measured using parent-reported diaries Following 6-months of active stimulation
Other Correlates of the scalp EEG with the intracranial recordings (local field potentials) from the DBS device. Analysis of local-field potentials measured from the DBS device in conjunction with data from the encephalography (EEG) data Following 6-months of active stimulation
Primary Adverse evens Measured according to pre-determined device-related AEs and SAEs, as well as generic AEs and SAEs. Following 6-months of active stimulation
Primary Willingness of the participants/parents/guardians for the participant to be recruited into the study and to undergo the intervention Consent at baseline Following 6-months of active stimulation
Primary Participant completion of the study Completion of all study activities at study exit Following 6-months of active stimulation
Primary Ability of the participant/parent(s)/guardian(s) to re-charge and maintain the device Device recharging is measured using the Picostim event logs Following 6-months of active stimulation
Secondary Relative change in parent-reported seizure frequency Measured using parent-reported diaries Following 6-months of active stimulation (compared to baseline)
Secondary Relative change in electrographic-recorded seizure frequency Measured using serial electroencephalography (EEG) Following 6-months of active stimulation (compared to baseline)
Secondary Relative change in seizure severity Measured using the Hague Seizure Severity Scoring questionnaire. Minimum score = 13; maximum score = 52; with higher seizure severity with ascending values. Following 6-months of active stimulation (compared to baseline)
Secondary Relative change in quality of life Measured on the Pediatric Quality of Life Inventory (PedsQL) questionnaire. The minimum score is 0 and the maximum score is 100, with improving quality of life with ascending values. Following 6-months of active stimulation (compared to baseline)
Secondary Relative change in quality of life Measured on the Impact of Pediatric Epilepsy Scale (IPES) questionnaires. The minimum score is 0 and the maximum score is 100, with improving quality of life with ascending values. Following 6-months of active stimulation (compared to baseline)
See also
  Status Clinical Trial Phase
Completed NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants Phase 1/Phase 2
Completed NCT02909387 - Adapting Project UPLIFT for Blacks in Georgia N/A
Completed NCT05552924 - Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients N/A
Terminated NCT01668654 - Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS Phase 3
Not yet recruiting NCT05068323 - Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients N/A
Completed NCT03994718 - Creative Arts II Study N/A
Recruiting NCT04076449 - Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Completed NCT00782249 - Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Active, not recruiting NCT06034353 - Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients N/A
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Not yet recruiting NCT06408428 - Glioma Intraoperative MicroElectroCorticoGraphy N/A
Not yet recruiting NCT05559060 - Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
Completed NCT02952456 - Phenomenological Approach of Epilepsy in Patients With Epilepsy
Completed NCT02646631 - Behavioral and Educational Tools to Improve Epilepsy Care N/A
Completed NCT02977208 - Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use Phase 4
Recruiting NCT02539134 - TAK-935 Multiple Rising Dose Study in Healthy Participants Phase 1
Terminated NCT02757547 - Transcranial Magnetic Stimulation for Epilepsy N/A
Completed NCT02491073 - Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL) N/A